Intervention not reported
Non‐serious adverse events · Children aged less than 5 years
1 finding from 1 review
Non‐serious adverse events Maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events Maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events 43 weeks · adults and children with chronic asthma
It is very uncertain whether increased changes non‐serious adverse events 43 weeks compared with stable doses of inhaled corticosteroids (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events considered non‐serious · people with leptospirosis
It is very uncertain whether summary of findings table ‐ Antibiotics changes adverse events considered non‐serious compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · liver transplant recipients
Normothermic machine perfusion (NMP) showed no clear difference in adverse events considered non‐serious compared with static cold storage (SCS) (moderate certainty).
1 finding from 1 review
Adverse events considered non‐serious · liver transplant recipients
1 finding from 1 review
Non‐serious adverse events: leukopenia · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).
1 finding from 1 review
Intervention not reported
Serious and non‐serious adverse events · people with asthma
1 finding from 1 review
All other (non‐serious) adverse events · people with chronic hepatitis C
1 finding from 1 review
Adverse events considered non‐serious · adult patients after liver transplantation.
It is very uncertain whether prostaglandin changes adverse events considered non‐serious ( compared with placebo or standard care (very low certainty).
1 finding from 1 review
Adverse events (non‐serious and serious) · people with diabetes and foot ulcers
Any growth factor showed no clear difference in adverse events (non‐serious and serious) compared with placebo or no growth factor (low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious adverse events for all placebos · patients with mental health disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events at 6 or 12 months · adults and children with strabismus
1 finding from 1 review
Non‐serious adverse events (range 2–10 months) · adult patients after liver transplantation.
1 finding from 1 review
Non‐serious adverse events (secondary outcome) · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether lactulose changes non‐serious adverse events (secondary outcome) compared with lactitol (very low certainty).
1 finding from 1 review
Non‐serious adverse events (secondary outcome) · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether non‐absorbable disaccharides changes non‐serious adverse events (secondary outcome) compared with placebo/no intervention (very low certainty).
1 finding from 1 review
Non‐serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
It is very uncertain whether L‐ornithine L‐aspartate changes non‐serious adverse events assessed using ICH‐GCP compared with lactulose (very low certainty).
1 finding from 1 review
Non‐serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found